Is It Time To Reconsider Sotera Health (SHC) After Recent Share Price Weakness?

• If you are wondering whether Sotera Health’s current share price still offers value, you are not alone. Many investors are asking the same question.
• The stock last closed at US$13.13, with returns of a 2.7% decline over 7 days, an 18.8% decline over 30 days, a 25.8% decline year to date, an 11.6% gain over 1 year, a 26.7% decline over 3 years, and a 47.5% decline over 5 years.
• Recent coverage has focused on Sotera Health as a recurring name in ongoing discussions about healthcare and life sciences businesses, keeping the stock on the radar for investors assessing long term opportunities. This continued attention helps frame how sentiment and expectations could be feeding into the current share price.
• The company currently has a valuation score of 4/6. The next sections will walk through the methods behind that assessment while hinting at an even richer way to think about value by the end of the article.

Sotera Health delivered 11.6% returns over the last year. See how this stacks up to the rest of the Life Sciences industry.

Approach 1: Sotera Health Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model estimates what a company could be worth today by projecting its future cash flows and discounting them back to the present.

For Sotera Health, the model used is a 2 Stage Free Cash Flow to Equity approach. The latest twelve month free cash flow is about $100.3 million. Analysts provide explicit free cash flow estimates up to 2028, where free cash flow is projected at $266.0 million, and Simply Wall St then extrapolates cash flows out to 2035, with discounted values for each year included in the model.

Bringing all of those projected cash flows back to today gives an estimated intrinsic value of about $19.56 per share. Compared with the recent share price of US$13.13, the model suggests the stock trades at roughly a 32.9% discount, which indicates that Sotera Health shares may be undervalued on this DCF view.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Sotera Health is undervalued by 32.9%. Track this in your watchlist or portfolio, or discover 61 more high quality undervalued stocks.

SHC Discounted Cash Flow as at Mar 2026

Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Sotera Health.

Approach 2: Sotera Health Price vs Earnings

P/E is a common way to value profitable companies because it connects what you pay for each share with the earnings that business is currently generating. In general, higher expected growth and lower perceived risk can justify a higher P/E, while lower growth expectations or higher risk tend to support a lower, more conservative P/E.

Sotera Health trades on a P/E of 47.91x, compared with the Life Sciences industry average of about 30.44x and a peer group average of 65.24x. Simply Wall St’s Fair Ratio for Sotera Health is 24.98x. This is its proprietary estimate of what a “normal” P/E could look like given factors such as earnings growth, profit margins, industry, market cap and company specific risks.

Fair Ratio can be more informative than a simple peer or industry comparison because it adjusts for these company specific features rather than assuming all Life Sciences businesses deserve the same P/E. On this measure, Sotera Health’s current P/E of 47.91x is higher than the Fair Ratio of 24.98x, which points to the shares looking overvalued on this earnings multiple view.

Result: OVERVALUED

NasdaqGS:SHC P/E Ratio as at Mar 2026

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 20 top founder-led companies.

Upgrade Your Decision Making: Choose your Sotera Health Narrative

Earlier it was mentioned that there is an even better way to understand valuation, so Narratives bring this to life by letting you set a clear story for Sotera Health, link that story to specific forecasts for revenue, earnings and margins, and turn those assumptions into a Fair Value that you can easily compare with the current share price, all within Simply Wall St’s Community page where Narratives are refreshed when new news or earnings arrive and where, for example, one Sotera Health Narrative might lean closer to the more optimistic US$24.00 fair value while another sits nearer to the cautious US$16.00 view, helping you see exactly how different assumptions lead to different conclusions about whether the market price looks rich or offers room for upside according to your own framework.

Do you think there’s more to the story for Sotera Health? Head over to our Community to see what others are saying!

NasdaqGS:SHC 1-Year Stock Price Chart

This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com